BioSpace News Archive

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the European Commission (EC) has granted approval of BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today the online publication of preclinical data in Cytotherapy, the official journal of the International Society of Cell and Gene Therapy (ISCT).

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023 at 10:00 a.m. Eastern Time in New York, NY.

Canadian life sciences company Ondine Biomedical has appointed Dr. Simon Sinclair as Chief Medical Officer, as the Company prepares to start the US Phase 3 trial of its nasal photodisinfection technology.

CoRegen announced today the publication of research, titled, “Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion,” in the peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS).

Biovica, active in cancer diagnostics, announces that a poster with DiviTum® TKa results from the SWOG study S0226 will be presented at the the world’s largest cancer conference, the annual ASCO meeting, on Sunday, June 4.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”) today announced positive data at Week 48 from Phase 2 trial (CN002) for icanbelimod (formerly known as CBP-307), a once-daily, orally administered, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator in development for the treatment of ulcerative colitis (UC).

Kyverna Therapeutics (“Kyverna”), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KYV-101 for the treatment of patients with refractory lupus nephritis (LN).

Dragonfly Therapeutics, Inc., announced it has expanded its clinical leadership team with the addition of Dr. Robin Edwards, previously Global Head of Translational Sciences at Daiichi Sankyo and Head of Translational at Bristol Myers Squibb, and Dr. David Ferry, previously Head of GI Oncology at Eli Lilly.

Shasqi, Inc. (“Shasqi”), a clinical-stage biotech company, whose mission is to revolutionize cancer treatment with click chemistry, announced today it has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc.